Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
IPO Year: 2020
Exchange: NASDAQ
Website: tayshagtx.com
Recent Analyst Ratings for Taysha Gene Therapies Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/27/2024 | $5.00 | Outperform | BMO Capital Markets |
4/9/2024 | $9.00 | Overweight | Piper Sandler |
2/1/2023 | $14.00 → $1.50 | Buy → Hold | Jefferies |
1/27/2023 | $23.00 → $3.00 | Overweight → Equal-Weight | Morgan Stanley |
11/9/2022 | $16.00 → $3.00 | Buy → Neutral | Goldman |
3/9/2022 | $26.00 | Outperform | Robert W. Baird |
3/9/2022 | $26.00 | Outperform | Baird |
3/1/2022 | $25.00 | Overweight | Wells Fargo |
2/18/2022 | $25.00 | Outperform | SMBC Nikko |
12/16/2021 | $28.00 | Buy | Guggenheim |
Taysha Gene Therapies Inc. Press Releases
Fastest customizable press release news feed in the world
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 491,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Ta
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 2, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 152,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development plan for TSHA-102 following initial RMAT Type B meeting FDA approved use of pivotal TSHA-102 product in REVEAL trials based on successful demonstration of analytical comparability; Company released pi
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Ta
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration achieved comparable biodistribution across brain and spinal cord regions in NHPs Findings from the analysis reaffirm the clinical potential of IT administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in both children and adults DALLAS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on adv
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635
Taysha Gene Therapies Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target
BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00
Piper Sandler initiated coverage on Taysha Gene Therapies with a new price target
Piper Sandler initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $9.00
Taysha Gene Therapies downgraded by Jefferies with a new price target
Jefferies downgraded Taysha Gene Therapies from Buy to Hold and set a new price target of $1.50 from $14.00 previously
Taysha Gene Therapies downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Taysha Gene Therapies from Overweight to Equal-Weight and set a new price target of $3.00 from $23.00 previously
Taysha Gene Therapies downgraded by Goldman with a new price target
Goldman downgraded Taysha Gene Therapies from Buy to Neutral and set a new price target of $3.00 from $16.00 previously
Robert W. Baird initiated coverage on Taysha Gene Therapies with a new price target
Robert W. Baird initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $26.00
Baird initiated coverage on Taysha Gene Therapies with a new price target
Baird initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $26.00
Wells Fargo initiated coverage on Taysha Gene Therapies with a new price target
Wells Fargo initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $25.00
SMBC Nikko initiated coverage on Taysha Gene Therapies with a new price target
SMBC Nikko initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $25.00
Guggenheim initiated coverage on Taysha Gene Therapies with a new price target
Guggenheim initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $28.00
Taysha Gene Therapies Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Manning Paul B bought $163,000 worth of shares (100,000 units at $1.63) (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Taysha Gene Therapies Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
CHIEF FINANCIAL OFFICER Alam Kamran covered exercise/tax liability with 29,843 shares, decreasing direct ownership by 2% to 1,242,094 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Chief Executive Officer Nolan Sean P. was granted 892,500 shares, increasing direct ownership by 75% to 2,078,358 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
President and Head of R&D Nagendran Sukumar was granted 324,500 shares, increasing direct ownership by 36% to 1,222,343 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
CHIEF FINANCIAL OFFICER Alam Kamran was granted 431,000 shares, increasing direct ownership by 51% to 1,271,937 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Long Alison S was granted 49,220 shares (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Stalfort John A Iii was granted 49,220 shares, increasing direct ownership by 5% to 1,098,601 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Donenberg Phillip B. was granted 49,220 shares, increasing direct ownership by 43% to 163,331 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Sepp-Lorenzino Laura was granted 49,220 shares (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Alam Kamran covered exercise/tax liability with 1,288 shares, decreasing direct ownership by 0.15% to 840,937 units (SEC Form 4)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
Taysha Gene Therapies Inc. SEC Filings
SEC Form 10-K filed by Taysha Gene Therapies Inc.
10-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SCHEDULE 13G filed by Taysha Gene Therapies Inc.
SCHEDULE 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form S-8 filed by Taysha Gene Therapies Inc.
S-8 - Taysha Gene Therapies, Inc. (0001806310) (Filer)
SEC Form EFFECT filed by Taysha Gene Therapies Inc.
EFFECT - Taysha Gene Therapies, Inc. (0001806310) (Filer)
SEC Form S-3 filed by Taysha Gene Therapies Inc.
S-3 - Taysha Gene Therapies, Inc. (0001806310) (Filer)
SEC Form 10-Q filed by Taysha Gene Therapies Inc.
10-Q - Taysha Gene Therapies, Inc. (0001806310) (Filer)
Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
Taysha Gene Therapies Inc. Leadership Updates
Live Leadership Updates
Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o
Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.
Taysha Gene Therapies Inc. Financials
Live finance-specific insights
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development plan for TSHA-102 following initial RMAT Type B meeting FDA approved use of pivotal TSHA-102 product in REVEAL trials based on successful demonstration of analytical comparability; Company released pi
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients TSHA-102 was generally well tolerated with no SAEs or DLTs as of initial six-week assessment in first patient in cohort two (high dose) of adolescent/adult trial; IDMC approved dosing of second (adolescent/adult trial) and first (pediatric trial) patient in cohort two, which is scheduled for Q3 2024 Cohort two (n=3) and cohort one (n=2) data from both trials (adolescent/adult and pediatric) expected in 1H 2
Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2024, and host a corporate update conference call and webcast on Monday, August 12, 2024, at 8:30 AM Eastern Time. Conference Call DetailsMonday, August 12, 2024, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free:877-407-0792International:201-689-8263Conference ID:13747741Webcast:https://ir.tayshagtx.com/news-events/events-presenta
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lowe
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024 Dosed second pediatric patient in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024 FDA granted Regenerative Medicine Advanced Therapy designation following review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL trials (adolescent/adult and pediatric) Initial data f
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern Time. Conference Call DetailsTuesday, May 14, at 4:30 PM Eastern Time / 3:30 PM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13745689Webcast: https://ir.tayshagtx.com/news-events/events-pres
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and new improvement in RSBQ at month six Data from second adult patient showed TSHA-102 (low dose, 5.7x1014 total vg) was well-tolerated with no treatment-emergent SAEs as of 19-week assessment, with sustained improvement across key efficacy measures, significantly reduced seizure events and new improvement in R-MBA at week 12 Principal Investigator observed sustained and new improvements across multiple clinical domains following
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time. Conference Call DetailsTuesday, March 19, at 4:30 PM Eastern Time / 3:30 PM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13744574W
Taysha Gene Therapies Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G filed by Taysha Gene Therapies Inc.
SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G filed by Taysha Gene Therapies Inc.
SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)